Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITESPARK-043: Extension Study of Belzutifan in Advanced Solid Tumors and VHL-related Tumors
NCT07405164Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Primary completion
- Apr 2034
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, open-label trial of belzutifan in solid tumor and von Hippel–Lindau disease (VHL) (3 cohorts), sponsored by Merck & Co. Primary endpoint: Overall Survival at 7 years. Started Mar 2026; status: recruiting.
02
Drugs
belzutifan
03
Conditions
solid tumorvon Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT07405164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405164.